Wecome Pharmaceutical Co Ltd (300878) — Cash Flow Reinvestment Rate
Wecome Pharmaceutical Co Ltd (300878) has a Cash Flow Reinvestment Rate of 0.03x as of June 2025, reinvesting CN¥1.47 Million (capex CN¥389.97K plus investments CN¥-1.08 Million) from operating cash flow of CN¥50.89 Million. Check Wecome Pharmaceutical Co Ltd (300878) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Wecome Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2013–2023)
Historical reinvestment intensity for Wecome Pharmaceutical Co Ltd across 10 annual periods. Explore cash flow to debt ratio of Wecome Pharmaceutical Co Ltd to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Wecome Pharmaceutical Co Ltd (2013–2023)
Year-by-year capital reinvestment analysis for Wecome Pharmaceutical Co Ltd. For live market cap and broader valuation context, see 300878 company net worth.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 6.52x | CN¥379.85 Million | CN¥58.29 Million | CN¥139.29 Million | ▲ +38.0% |
| 2022 | 4.72x | CN¥692.26 Million | CN¥146.57 Million | CN¥248.44 Million | ▲ +17.4% |
| 2020 | 4.02x | CN¥172.30 Million | CN¥42.81 Million | CN¥152.34 Million | ▲ +236.3% |
| 2019 | 1.20x | CN¥134.94 Million | CN¥112.76 Million | CN¥114.98 Million | ▼ -34.4% |
| 2018 | 1.83x | CN¥192.69 Million | CN¥105.57 Million | CN¥172.73 Million | ▼ -14.6% |
| 2017 | 2.14x | CN¥62.00 Million | CN¥29.00 Million | CN¥42.04 Million | ▲ +124.2% |
| 2016 | 0.95x | CN¥95.51 Million | CN¥100.15 Million | CN¥47.97 Million | ▼ -26.6% |
| 2015 | 1.30x | CN¥38.48 Million | CN¥29.63 Million | CN¥38.48 Million | ▲ +46.9% |
| 2014 | 0.88x | CN¥40.68 Million | CN¥46.01 Million | CN¥40.68 Million | ▲ +100.2% |
| 2013 | 0.44x | CN¥11.48 Million | CN¥25.98 Million | CN¥11.48 Million | — |